NO975975L - Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav - Google Patents

Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav

Info

Publication number
NO975975L
NO975975L NO975975A NO975975A NO975975L NO 975975 L NO975975 L NO 975975L NO 975975 A NO975975 A NO 975975A NO 975975 A NO975975 A NO 975975A NO 975975 L NO975975 L NO 975975L
Authority
NO
Norway
Prior art keywords
preparation
receptor antagonists
vitronectin receptor
vitronectin
meanings
Prior art date
Application number
NO975975A
Other languages
English (en)
Other versions
NO975975D0 (no
Inventor
Volkmar Wehner
Hans Ulrich Stilz
Anuschirwan Peyman
Karlheinz Scheunemann
Jean-Marie Ruxer
Denis Carniato
Jean-Michel Lefrancois
Thomas Richard Gadek
Robert Mcdowell
Original Assignee
Hoechst Ag
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag, Genentech Inc filed Critical Hoechst Ag
Publication of NO975975D0 publication Critical patent/NO975975D0/no
Publication of NO975975L publication Critical patent/NO975975L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Abstract

Det er beskrevet forbindelser med formel I, A-B-D-E-F-G (D hvor A, B, D, E, F og G har de i patentkravene angitte betydninger, fremstilling og anvendelse derav som legemiddel. Forbindelsene anvendes også som vitronektinreseptor-antagonister og som inhibitorer av benresorpsjon.
NO975975A 1996-12-20 1997-12-19 Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav NO975975L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19653645A DE19653645A1 (de) 1996-12-20 1996-12-20 Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung

Publications (2)

Publication Number Publication Date
NO975975D0 NO975975D0 (no) 1997-12-19
NO975975L true NO975975L (no) 1998-06-22

Family

ID=7815760

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975975A NO975975L (no) 1996-12-20 1997-12-19 Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav

Country Status (19)

Country Link
US (1) US5990145A (no)
EP (1) EP0854145A3 (no)
JP (1) JPH10182617A (no)
KR (1) KR19980064419A (no)
CN (1) CN1200373A (no)
AR (1) AR010369A1 (no)
AU (1) AU729760B2 (no)
BR (1) BR9706386A (no)
CA (1) CA2225267A1 (no)
CZ (1) CZ411297A3 (no)
DE (1) DE19653645A1 (no)
HU (1) HUP9702509A3 (no)
ID (1) ID19245A (no)
IL (1) IL122643A0 (no)
NO (1) NO975975L (no)
NZ (1) NZ329429A (no)
PL (1) PL323968A1 (no)
TR (1) TR199701645A2 (no)
ZA (1) ZA9711315B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19647380A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
BR9916518A (pt) 1998-12-23 2002-01-29 Searle & Co Método para tratar ou prevenir um distúrbio de neoplasia em um mamìfero em necessidade de tal tratamento ou prevenção, e, combinação compreendendo um inibidor de ciclooxigenase-2 e um ou mais agentes anti-neoplásticos
US6545032B1 (en) * 1999-09-17 2003-04-08 Torrey Pines Institute For Molecular Studies Synthesis of [3,5,7]-H-imidazo[1,5-a] imidazol-2(3H)-one compounds
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
DK1371646T3 (da) * 2001-03-19 2010-07-05 Dainippon Sumitomo Pharma Co Arylsubstitueret alicyklisk forbindelse og medicinsk præparat omfattende det samme
KR100861466B1 (ko) 2001-04-24 2008-10-02 메르크 파텐트 게엠베하 항혈관형성제 및 ＴＮＦα를 이용한 병용 요법
JP4750360B2 (ja) 2001-10-22 2011-08-17 ザ スクリプス リサーチ インスティチュート 抗体ターゲッティング化合物
NZ532463A (en) 2001-11-13 2007-02-23 Dimensional Pharm Inc Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
US7205315B2 (en) * 2003-09-27 2007-04-17 Sanofi-Aventis Deutschland Gmbh Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases
US20070122408A1 (en) * 2005-10-20 2007-05-31 The Scripps Research Institute Fc Labeling for Immunostaining and Immunotargeting
US8618115B2 (en) * 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
JP2009523813A (ja) 2006-01-18 2009-06-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌を治療するためにインテグリンのリガンドを使用する特異的な治療法
US7553836B2 (en) * 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
KR20090108713A (ko) 2007-01-18 2009-10-16 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약
CA2680275C (en) 2007-03-09 2016-08-23 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
PE20091928A1 (es) * 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
CN106572997A (zh) 2014-05-30 2017-04-19 辉瑞公司 作为选择性雄激素受体调节剂的腈衍生物
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE228115T1 (de) * 1991-06-28 2002-12-15 Smithkline Beecham Corp Bizyklische fibrinogenantagonisten
US5204350A (en) * 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
US5217994A (en) * 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
AU674553B2 (en) * 1992-10-14 1997-01-02 Merck & Co., Inc. Fibrinogen receptor antagonists
AU675689B2 (en) * 1992-12-01 1997-02-13 Merck & Co., Inc. Fibrinogen receptor antagonists
AU689762B2 (en) * 1992-12-21 1998-04-09 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
EP0760658B1 (en) * 1994-05-27 2002-11-13 Merck & Co. Inc. Compounds for inhibiting osteoclast-mediated bone resorption
WO1996000574A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
NZ290008A (en) * 1994-06-29 1998-08-26 Smithkline Beecham Corp Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
DE19516483A1 (de) * 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
PT910563E (pt) * 1995-06-29 2003-09-30 Smithkline Beecham Corp Antagonistas de receptores de integrina
HUP9901116A2 (hu) * 1995-12-29 2000-03-28 Smithkline Beecham Corporation Vitronektin receptor antagonisták
TR199801253T2 (xx) * 1995-12-29 1998-12-21 Smithkline Beecham Corporation Vitronektin resept�r� antagonistleri.
CN1209063A (zh) * 1995-12-29 1999-02-24 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
DE59706273D1 (de) * 1996-03-20 2002-03-21 Hoechst Ag Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19629817A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten

Also Published As

Publication number Publication date
HUP9702509A3 (en) 2001-04-28
BR9706386A (pt) 2003-04-22
TR199701645A3 (tr) 1998-07-21
MX9710389A (es) 1998-08-30
CZ411297A3 (cs) 1998-07-15
US5990145A (en) 1999-11-23
PL323968A1 (en) 1998-06-22
NO975975D0 (no) 1997-12-19
NZ329429A (en) 1999-05-28
JPH10182617A (ja) 1998-07-07
AU729760B2 (en) 2001-02-08
AU4846497A (en) 1998-06-25
ID19245A (id) 1998-06-28
KR19980064419A (ko) 1998-10-07
DE19653645A1 (de) 1998-06-25
ZA9711315B (en) 1998-06-22
HUP9702509A2 (hu) 1999-06-28
IL122643A0 (en) 1998-08-16
AR010369A1 (es) 2000-06-07
CA2225267A1 (en) 1998-06-20
HU9702509D0 (en) 1998-03-02
EP0854145A2 (de) 1998-07-22
CN1200373A (zh) 1998-12-02
TR199701645A2 (xx) 1998-07-21
EP0854145A3 (de) 2000-03-22

Similar Documents

Publication Publication Date Title
NO975975L (no) Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav
NO983002L (no) Vitronectin-reseptor-antagonister
CA2211270A1 (en) Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
TR199801253T2 (xx) Vitronektin resept�r� antagonistleri.
TR200000812T2 (tr) 2-metil-tieno- benzodiazepin formülasyonu.
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
BG104544A (en) Novel acylguanadine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists
NO20001514L (no) Vitronectin-reseptor-antagonist
NO20020574D0 (no) Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden
NO990662L (no) Trombin-inhibitorer
FR2684289B1 (fr) Implant intra-cortical, notamment pour la fixation de ligament.
IT1283232B1 (it) Procedimento per la sintesi di 2-buten-1, 4-diesteri
TR200100885T2 (tr) 2-Metil-tieno-benzodiazepin formülasyonu
NO973652D0 (no) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyre og derivater som tachykininreseptor-antagonist
BR9813214A (pt) Antagonista de receptor vitronectina
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
TR200101654T2 (tr) Vitronektin resept”r antagonistleri
ATE282417T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
WO2000007544A3 (en) Vitronectin receptor antagonists
NO20000518L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
MY132635A (en) Cycloalkyl derivatives as inhibitors of bone resporption and vitronectin receptor antagonists
NO981135L (no) Syreaddisjonssalter av 2,3,4,5-tetrahydro-1H-3-benzazepinforbindelser
TR199701646A2 (xx) Vitronektin-reseptör antagonistleri,üretimleri ve kullanımları

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application